1. Home
  2. CAN vs RIGL Comparison

CAN vs RIGL Comparison

Compare CAN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAN
  • RIGL
  • Stock Information
  • Founded
  • CAN 2013
  • RIGL 1996
  • Country
  • CAN Singapore
  • RIGL United States
  • Employees
  • CAN N/A
  • RIGL N/A
  • Industry
  • CAN Semiconductors
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAN Technology
  • RIGL Health Care
  • Exchange
  • CAN Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • CAN 330.5M
  • RIGL 335.5M
  • IPO Year
  • CAN 2019
  • RIGL 2000
  • Fundamental
  • Price
  • CAN $0.74
  • RIGL $38.85
  • Analyst Decision
  • CAN Strong Buy
  • RIGL Buy
  • Analyst Count
  • CAN 6
  • RIGL 5
  • Target Price
  • CAN $2.50
  • RIGL $38.20
  • AVG Volume (30 Days)
  • CAN 32.6M
  • RIGL 995.6K
  • Earning Date
  • CAN 08-14-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • CAN N/A
  • RIGL N/A
  • EPS Growth
  • CAN N/A
  • RIGL N/A
  • EPS
  • CAN N/A
  • RIGL 5.43
  • Revenue
  • CAN $345,360,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • CAN $90.25
  • RIGL $59.93
  • Revenue Next Year
  • CAN $42.94
  • RIGL N/A
  • P/E Ratio
  • CAN N/A
  • RIGL $7.15
  • Revenue Growth
  • CAN 82.40
  • RIGL 105.62
  • 52 Week Low
  • CAN $0.53
  • RIGL $12.66
  • 52 Week High
  • CAN $3.27
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • CAN 51.63
  • RIGL 68.57
  • Support Level
  • CAN $0.64
  • RIGL $39.00
  • Resistance Level
  • CAN $0.80
  • RIGL $42.08
  • Average True Range (ATR)
  • CAN 0.05
  • RIGL 2.32
  • MACD
  • CAN 0.00
  • RIGL -0.37
  • Stochastic Oscillator
  • CAN 59.38
  • RIGL 53.26

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: